Article Page

Abstract

Recently, it is shown that there is a crucial contradiction within von Neumann’s theory [K. Nagata and T. Nakamura, Int. J. Theor. Phys. 49, 162 (2010)]. We derive a proposition concerning a quantum expected value under the assumption of the existence of the directions in a spin-1/2 system. The quantum predictions within the formalism of von Neumann’s projective measurement cannot coexist with the proposition concerning the existence of the directions. Therefore, we have to give up either the existence of the directions or the formalism of von Neumann’s projective measurement. Hence, there is a crucial contradiction within von Neumann’s theory. We discuss that this crucial contradiction makes the theoretical formulation of Deutsch’s algorithm questionable. Especially, we systematically describe our assertion based on more mathematical analysis using raw data. Our discussion, here, improves Can Von Neumann’s Quantum Computation Theory on Protein−Ligand Hyper drug-target Complexes interaction analysis for the in silico free energy potency optimization of a poly-targeted binding-pocket peptide mimic annotated chemo-antagonists to HIV-II viral replication cycle associated enzymes.

Keywords

Can Von Neumann’s Theory; Quantum Computation; Protein−Ligand; Hyper drug-target Complexes; interaction analysis; in silico; free energy; potency optimization; poly-targeted; binding-pocket; peptide mimic; annotated chemo-antagonists; HIV-II viral replication; cycle associated enzymes, Quantum Measurement Theory, Quantum Computer, Formalism, Subject Areas: Applied Physics

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Can Von Neumann’s Quantum Computation Theory on Protein−Ligand Hyper drug-target Complexes interaction analysis for the in silico free energy potency optimization of a poly-targeted binding-pocket peptide mimic annotated chemo-antagonists to HIV-II viral replication cycle associated enzymes.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available